Catalyst

Slingshot members are tracking this event:

Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
INCY Community voting in process

Additional Information

Additional Relevant Details  Incyte Corporation today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte’s investigational, highly potent and selective oral IDO1 inhibitor, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Incyte expects initial data from the ECHO-301 study to be available in 2018.
http://phx.corporate...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Echo-301, Phase 3, Keytruda, Pembrolizumab